Ayala Pharmaceuticals, Inc. – NASDAQ:AYLA

Financial Health
0
1
2
3
4
5
6
7
8
9

Ayala Pharmaceuticals stock price monthly change

+25.65%
month

Ayala Pharmaceuticals stock price quarterly change

-28.27%
quarter

Ayala Pharmaceuticals stock price yearly change

-90.98%
year

Ayala Pharmaceuticals key metrics

Market Cap
N/A
Enterprise value
N/A
P/E
-0.27
EV/Sales
-4.31
EV/EBITDA
0.08
Price/Sales
14.08
Price/Book
1.01
PEG ratio
N/A
EPS
-2.48
Revenue
692K
EBITDA
-37.42M
Income
-38.01M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-5182.28%
Oper. margin
-5059.97%
Gross margin
-179.9%
EBIT margin
-5059.97%
EBITDA margin
-5408.82%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ayala Pharmaceuticals stock price history

Ayala Pharmaceuticals stock forecast

Ayala Pharmaceuticals financial statements

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Profit margin
Mar 2022 458K -10.02M -2189.3%
Jun 2022 38K -8.21M -21605.26%
Sep 2022 91K -10.18M -11195.6%
Dec 2022 105K -9.58M -9131.43%
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Earnings per share (EPS)
2022-05-16 -0.68 -0.66
2022-08-15 -0.65 -0.54
2022-11-04 -0.49 -0.66
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Debt to assets
Mar 2022 30647000 5.82M 19.02%
Jun 2022 1270000 6.66M 524.49%
Sep 2022 14260000 6.10M 42.78%
Dec 2022 4581000 5.68M 123.99%
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Cash Flow
Mar 2022 -9.98M 0 44K
Jun 2022 -7.02M 0 44K
Sep 2022 -9.33M 0 468K
Dec 2022 -8.16M -2K -615K

Ayala Pharmaceuticals alternative data

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Employee count
Aug 2023 35
Sep 2023 35
Oct 2023 35
Nov 2023 35
Dec 2023 35
Jan 2024 35
Feb 2024 35
Mar 2024 35
Apr 2024 35
May 2024 35
Jun 2024 35
Jul 2024 35

Ayala Pharmaceuticals other data

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Insider trades (number of shares)
Period Buy Sel
May 2020 1575225 0
Jul 2020 5 0
Aug 2020 5 0
Sep 2020 11 0
Dec 2020 4 0
Jan 2021 0 23872
Feb 2021 0 36126
Transaction Date Insider Security Shares Price per share Total value Source
Option
GORDON GARY B. officer: Chief Me.. Common Stock 3,000 $5.16 $15,480
Option
GORDON GARY B. officer: Chief Me.. Stock Option 3,000 $5.16 $15,480
Sale
GORDON GARY B. officer: Chief Me.. Common Stock 3,000 $5.16 $15,480
Sale
MAMLUK RONI director, officer.. Common Stock 10,800 $17.4 $187,920
Sale
MAMLUK RONI director, officer.. Common Stock 7,126 N/A N/A
Sale
MAMLUK RONI director, officer.. Common Stock 15,200 N/A N/A
Sale
MAMLUK RONI director, officer.. Common Stock 1,406 N/A N/A
Option
GORDON GARY B. officer: Chief Me.. Stock Option 3,000 N/A N/A
Sale
GORDON GARY B. officer: Chief Me.. Common Stock 3,000 N/A N/A
Option
GORDON GARY B. officer: Chief Me.. Common Stock 3,000 N/A N/A
Patent
Application
Filling date: 14 May 2020 Issue date: 4 Aug 2022
Application
Filling date: 6 May 2019 Issue date: 9 Dec 2021
Application
Filling date: 5 May 2019 Issue date: 12 Aug 2021
Application
Filling date: 22 Oct 2020 Issue date: 11 Feb 2021
Application
Filling date: 24 Sep 2019 Issue date: 19 Mar 2020
Application
Filling date: 27 Sep 2019 Issue date: 23 Jan 2020
Insider Compensation
Mr. Yossi Maimon CPA, M.B.A., CPA, MBA (1971) Chief Financial Officer, Sec. & Treasurer
$692,180
Dr. Roni Mamluk Ph.D. (1967) Pres, Chief Executive Officer & Director $635,600
Dr. Gary B. Gordon M.D., Ph.D. (1953) Chief Medical Officer $550,310
Wednesday, 19 October 2022
businesswire.com
Tuesday, 13 September 2022
Zacks Investment Research
Wednesday, 24 August 2022
GlobeNewsWire
Tuesday, 16 August 2022
InvestorPlace
Monday, 15 August 2022
Zacks Investment Research
Monday, 1 August 2022
PennyStocks
Thursday, 2 June 2022
GlobeNewsWire
Monday, 16 May 2022
Zacks Investment Research
Monday, 28 March 2022
Zacks Investment Research
Wednesday, 9 March 2022
GlobeNewsWire
Thursday, 6 January 2022
GlobeNewsWire
Thursday, 18 November 2021
Zacks Investment Research
Monday, 15 November 2021
Zacks Investment Research
Wednesday, 10 November 2021
GlobeNewsWire
Tuesday, 9 November 2021
Zacks Investment Research
Thursday, 16 September 2021
Benzinga
Thursday, 2 September 2021
GlobeNewsWire
Friday, 13 August 2021
Zacks Investment Research
Benzinga
GlobeNewsWire
  • When is Ayala Pharmaceuticals's next earnings date?

    Unfortunately, Ayala Pharmaceuticals's (AYLA) next earnings date is currently unknown.

  • Does Ayala Pharmaceuticals pay dividends?

    No, Ayala Pharmaceuticals does not pay dividends.

  • What is Ayala Pharmaceuticals's stock symbol?

    Ayala Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AYLA".

  • What is Ayala Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Ayala Pharmaceuticals?

    Shares of Ayala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Ayala Pharmaceuticals's key executives?

    Ayala Pharmaceuticals's management team includes the following people:

    • Mr. Yossi Maimon CPA, M.B.A., CPA, MBA Chief Financial Officer, Sec. & Treasurer(age: 54, pay: $692,180)
    • Dr. Roni Mamluk Ph.D. Pres, Chief Executive Officer & Director(age: 58, pay: $635,600)
    • Dr. Gary B. Gordon M.D., Ph.D. Chief Medical Officer(age: 72, pay: $550,310)
  • How many employees does Ayala Pharmaceuticals have?

    As Jul 2024, Ayala Pharmaceuticals employs 35 workers.

  • When Ayala Pharmaceuticals went public?

    Ayala Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 8 May 2020.

  • What is Ayala Pharmaceuticals's official website?

    The official website for Ayala Pharmaceuticals is ayalapharma.com.

  • How can i contact Ayala Pharmaceuticals?

    Ayala Pharmaceuticals can be reached via phone at 857 444 0553.

Ayala Pharmaceuticals company profile:

Ayala Pharmaceuticals, Inc.

ayalapharma.com
Exchange:

NASDAQ

Full time employees:

35

Industry:

Biotechnology

Sector:

Healthcare

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

4 Oppenheimer Street
Rehovot, 7670104

CIK: 0001797336
ISIN: US05465V1089
CUSIP: 05465V108